Product Description
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Rakuten Medical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: India, Japan, Taiwan, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Head and Neck Cancer
Phase 2: Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ASP-1929-301 | P3 |
Recruiting |
Head and Neck Cancer |
2025-12-01 |
|
ASP-1929-103 | P2 |
Active, not recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma |
2024-07-11 |
|
ASP-1929-181 | P2 |
Active, not recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma |
2024-06-01 |
57% |